Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021

Buil, Jochem B.; Zanten, Arthur R. H. van; Bentvelsen, Robbert G.; Rijpstra, Tom A.; Goorhuis, Abraham; Voort, Sanne van der; Wammes, Linda J.; Janson, J. A.; Melchers, Max; Heusinkveld, Moniek; Melchers, Willem J. G.; Kuijper, Ed J.; Verweij, Paul E.

doi:10.2807/1560-7917.es.2021.26.23.2100510

Cited by 56 publications

(33 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…and Rhizopus microsporus. Interestingly, of the seven reported CAM cases by R. microsporus, six were pulmonary (including one disseminated), and the other was a case of cutaneous mucormycosis [2,14,20,28,31,43]. Probably, the relatively smaller size of the R. microsporus sporangiospores (compared to R. arrhizus) might have lodged them in the lower airways causing pulmonary infection, which needs to be studied further.…”

Section: Epidemiology Of Cam In India Versus the Rest Of The Worldmentioning

confidence: 99%

Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World

et al. 2021

View full text Add to dashboard Cite

Section: Epidemiology Of Cam In India Versus the Rest Of The Worldmentioning

confidence: 99%

Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World

et al. 2021

View full text Add to dashboard Cite

“…The majority of cases (84.7%) were diagnosed during the clinical course of COVID-19, for which more half of the patients received systemic steroid treatment, and only 13.6% at least one dose of tocilizumab. The most frequent clinical presentations of mucormycosis (i9 cases each, 32.3%) were rhino-orbital [144,145,151,154,159,[161][162][163][164]166] and rhino-orbitocerebral [143,[146][147][148][151][152][153]155,157,163,165], followed by 12 cases of pulmonary disease (20.3%) [84,88,138,139,141,144,147,149,167]. Autopsies of two cases revealed disseminated mucormycosis [144,158].…”

Section: Case Reports and Case Seriesmentioning

confidence: 99%

“…Histopathological examinations (HPEs) were carried out in all cases, 91.5% of which were positive; the diagnosis of the remaining five cases was supported by cultures of infected specimens (BAL, sputum, and purulent orbital material) [147,165]. Twenty-nine diagnoses of fungal rhinosinusitis were made on the basis of HPEs of nasal biopsies obtained during functional endoscopic sinus surgery (FESS); a further 10 diagnoses were based on HPEs of nasal material obtained by other means (discharges, scrapings, aspirates, or swabs).…”

Section: Case Reports and Case Seriesmentioning

confidence: 99%

“…Twenty-nine diagnoses of fungal rhinosinusitis were made on the basis of HPEs of nasal biopsies obtained during functional endoscopic sinus surgery (FESS); a further 10 diagnoses were based on HPEs of nasal material obtained by other means (discharges, scrapings, aspirates, or swabs). Definite diagnoses of pleuro-pulmonary mucormycosis were made after HPEs of BAL (three cases), a pulmonary biopsy (one case), pleural effusion (one case), a pleural biopsy (one case), induced sputum (one case), and BAL plus a pulmonary biopsy (one case) [84,88,138,139,141,145,147,149,167].…”

Section: Case Reports and Case Seriesmentioning

confidence: 99%

See 1 more Smart Citation

Invasive Fungal Infections Complicating COVID-19: A Narrative Review

Casalini

Giacomelli

Ridolfo

et al. 2021

JoF

View full text Add to dashboard Cite

Invasive fungal infections (IFIs) can complicate the clinical course of COVID-19 and are associated with a significant increase in mortality, especially in critically ill patients admitted to an intensive care unit (ICU). This narrative review concerns 4099 cases of IFIs in 58,784 COVID-19 patients involved in 168 studies. COVID-19-associated invasive pulmonary aspergillosis (CAPA) is a diagnostic challenge because its non-specific clinical/imaging features and the fact that the proposed clinically diagnostic algorithms do not really apply to COVID-19 patients. Forty-seven observational studies and 41 case reports have described a total of 478 CAPA cases that were mainly diagnosed on the basis of cultured respiratory specimens and/or biomarkers/molecular biology, usually without histopathological confirmation. Candidemia is a widely described secondary infection in critically ill patients undergoing prolonged hospitalisation, and the case reports and observational studies of 401 cases indicate high crude mortality rates of 56.1% and 74.8%, respectively. COVID-19 patients are often characterised by the presence of known risk factors for candidemia such as in-dwelling vascular catheters, mechanical ventilation, and broad-spectrum antibiotics. We also describe 3185 cases of mucormycosis (including 1549 cases of rhino-orbital mucormycosis (48.6%)), for which the main risk factor is a history of poorly controlled diabetes mellitus (>76%). Its diagnosis involves a histopathological examination of tissue biopsies, and its treatment requires anti-fungal therapy combined with aggressive surgical resection/debridement, but crude mortality rates are again high: 50.8% in case reports and 16% in observational studies. The presence of other secondary IFIs usually diagnosed in severely immunocompromised patients show that SARS-CoV-2 is capable of stunning the host immune system: 20 cases of Pneumocystis jirovecii pneumonia, 5 cases of cryptococcosis, 4 cases of histoplasmosis, 1 case of coccidioides infection, 1 case of pulmonary infection due to Fusarium spp., and 1 case of pulmonary infection due to Scedosporium.

show abstract

“…Indeed, several cases of peritoneal-dialysis-associated mucormycosis have been described [6,[38][39][40]. Most recently, steroid therapy of COVID-19 infections has been identified as another risk factor [41][42][43][44]. Molecular diagnostic approaches for the early and reliable diagnosis of systemic infections are presently under investigation [45].…”

Section: Introductionmentioning

confidence: 99%

Risk Assessment for Molds in the Vicinity of a Child Requiring Peritoneal Dialysis Living in a Rural Northern German Area

Zautner

Frickmann

Podbielski³

2021

Microorganisms

View full text Add to dashboard Cite

As well as severe immunosuppression, other predisposing factors may facilitate invasive mycosis caused by molds. Chronic kidney disease and the resulting peritoneal dialysis have been reported as factors putting patients at risk of fungal infections from environmental sources. We describe an environmental investigation undertaken to guide exposure prevention for a peritoneal dialysis patient with transient colonization of her nostrils by Lichtheimia corymbifera in a rural area of northern Germany. Systematic screening for airborne and surface-deposited molds enabled targeted recommendations to be made, although Lichtheimia corymbifera itself was not grown from the collected environmental samples. This communication is intended to illustrate how such an investigation can be performed on the basis of the environmental distribution of the molds and how preventive recommendations can be derived from the results.

show abstract

Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021

Cited by 56 publications

References 17 publications

Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World

Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World

Invasive Fungal Infections Complicating COVID-19: A Narrative Review

Risk Assessment for Molds in the Vicinity of a Child Requiring Peritoneal Dialysis Living in a Rural Northern German Area

Contact Info

Product

Resources

About